Budesonide in the treatment of idiopathic intestinal inflammation
Milan Lukáš Orcid.org 1
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Lukáš M, Dušek L. Idiopatické střevní záněty ve statistických ukazatelích a analýzách. In: Lukáš M (ed). Idiopatické střevní záněty. Nové trendy a mezioborové souvislosti. Praha: Grada 2020.
2. Truleove SC, Witts IJ. Cortisone in ulcerative colitis. Final report on therapeutic trial. Br Med J 1955; 2: 1041–1048. doi: 10.1136/bmj.2.4947.1041.
3. Modigliani R, Mary JY,Simon JF et al. Clinical, endoscopic and biological picture of attacks of Crohn’s disease. Gastroenterology 1990; 98: 811–818. doi: 10.1016/0016-5085 (90) 90002-i.
4. Lukáš M. Pokroky v medikamentózní konvenční léčbě. In: Lukáš M (ed). Pokroky v diagnostice a léčbě idiopatických střevních zánětů. Praha: Galen 2019.
5. Rezaie A, Kuenzig ME, Benchimol EI et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2015; doi: 10.1002/14651858.CD000296.pub4.
6. Thomson O, Cortot A, Jewell DP et al. A comparison of budesonide and mesalamine for Crohn’s disease. International budesonide mesalamine study group. N Engl J Med 1998; 339: 370–374. doi: 10.1056/NEJM199808063390603.
7. Tromm J, Bunganič I, Tomsová E et al. Budesonide 9 mg is at least as effective as mesalamine 4.5g in patients with mildly to moderately active Crohn´s disease. Gastroenterology 2011; 140 (2): 425–434. doi: 10.1053/j.gastro.2010.11.004.
8. Kuenzig ME, Rezaie A, Seow CH et al. Budenoside for maintenance of remission in Crohn’s Disease. Cochrane Database Syst Rev 2017. doi: 10.1002/14651858.CD002913.pub3.
9. Travis SL, Danese S, Kapcinskas L et al. Once daily budesonide MMX in active mild to moderate ulcerative colitis“ results from the randomized CORE II study. Gut 2014; 63 (3): 433–441. doi: 10.1136/gutjnl-2012-304258.
10. Hrdlička L, Bortlík M, Douda T et al. Budesonid MMX (Cortiment 9 mg) v léčbě ulcerózní kolitidy v reálné klinické praxi. Gastroent Hepatol 2016; 70 (6): 509–513. doi: 10.14735/amgh2016509.
11. Gross V, Bar-Meir A, Lavy O et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther 2006; 23: 303–312. doi: 10.1111/j.1365-2036.2006.02 743.x.
12. Kafil TS, Nguyen TM, Patton PH et al. Intervention for treating collagenous colitis. Cochrane Database Syst Rev 217. doi: 10.1002/14651858.CD003575.pub6.
13. Reilev M, Hallas J, Ernst MT et al. Long-term oral budesonide treatment and risk of osteoporotic fractures in patients with microscopic colitis. Aliment Pharmacol Ther 2020; 51 (6): 644–651. doi: 10.1111/apt.15648.